IP Library Granted Patent US 11,638,548
Granted Patent B2
US 11,638,548 · App. 16/162,136 · Granted May 2, 2023

Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities

Inventors: Allan Kumar Mishra (Menlo Park, CA); Todd Jeffrey Brinton (Menlo Park, CA)
Assignee: Blue Engine Biologies, LLC
A61B5/318A61B5/4848A61K9/0073A61K35/16A61K35/19A61K45/06A61M15/009A61M16/14A61N1/36114C12N5/0644A61M2202/0007A61M2202/0415A61M2202/0427A61N1/3629
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,638,548
App. No.
16/162,136
Granted
May 2, 2023
Kind
B2
Abstract

Methods and kits for treating a cardiac arrhythmia using a platelet rich plasma (PRP) composition are provided. Any type of arrhythmia may be treated using the PRP composition. The PRP composition may comprise PRP developed using blood collected from a patient suffering the cardiac arrhythmia. The PRP composition may be buffered to a physiological pH and may include one or more anti-arrhythmic agents, anti-coagulants, or other drugs. The PRP composition may be delivered using a nebulizer, minimally invasively, or surgically.

Claims (14)

1. A method for treating a tissue injury, comprising:

identifying a tissue injury in a patient;

preparing PRP in an inhalable form comprising:

collecting blood from a patient;

isolating platelets from the collected blood;

suspending the isolated platelets in plasma to form a PRP composition;

providing the PRP composition in an inhaler or nebulizer; and

delivering the PRP composition to the patient by inhalation in an amount sufficient to treat the tissue injury.

2. The method of claim 1 , wherein the PRP composition is prepared from whole blood of the patient.

3. The method of claim 1 , wherein the PRP composition is buffered to a physiological pH, and wherein the physiological pH is between about 7.3 and about 7.5.

4. The method of claim 1 , wherein the inhalable form is an inhalable powder.

5. The method of claim 1 , wherein the injured tissue is an internal organ.

6. The method of claim 1 , wherein the injured tissue is selected from the group consisting of heart, stomach, abdominal wall, bladder, and vascular tissue.

7. The method of claim 1 , wherein the inhalable form is a dry powder.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2021
From: MISHRA, ALLAN, DR.
To: BLUE ENGINE BIOLOGICS, LLC
Reel/Frame 056759/0943 →